GRAL
GRAIL, LLC
NASDAQ: GRAL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$61.26
-9.87% today
Updated 2026-06-05
Market cap
$2.57B
P/E ratio
—
P/S ratio
16.45x
EPS (TTM)
$-10.30
Dividend yield
—
52W range
$30 – $119
Volume
0.8M
GRAIL, LLC (GRAL) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed GRAL price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$61.26
Today
Analyst consensus
$67.88
+10.81% · 12M
2030 Base
$102.35
+67.07% future
NPV today
$65.96
@ 10% WACC
8 analysts:
4 Buy3 Hold1 Sell
Management guidance
GRAIL guided to 2030 cash runway, indicating confidence in multi-year operation and revenue growth trajectory. CEO Josh Ofman (appointed March 2026) has emphasized strong clinical utility, physician adoption, and commercial partnerships as growth drivers. No specific revenue targets disclosed, but company projects sustained operations through 2030 with current cash position of $823.1M (Q1 2026).
Sources: Management guidance, analyst consensus, sector analysishigh confidence
GRAL · GRAIL, LLC · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$39.87
NPV today: $25.69
Base case (2030)
$102.35
NPV today: $65.96
Bull case (2030)
$227.33
NPV today: $146.50
WallStSmart.com
GRAL financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.2B | $0.3B | $0.4B | $0.6B | $0.8B |
| Revenue growth | 17.2% | 24.5% | 52.9% | 45.8% | 39.8% | 33.3% |
| Net margin | — | -273.2% | -170.4% | -99.9% | -51.8% | -22.4% |
| EPS | $-11.18 | $-11.31 | $-10.50 | $-8.75 | $-6.20 | $-3.50 |
| Diluted shares | — | 44M | 45M | 47M | 48M | 49M |
| Net debt | — | $91.50M | $231.50M | $435.50M | $720.50M | $1.10B |
| P/S multiple | — | 8.0x | 8.0x | 8.0x | 8.0x | 8.0x |
| Implied price (base) | — | $31.05 | $44.20 | $60.73 | $80.58 | $102.35 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $0.8B | $0.8B | $0.8B |
| P/S multiple | 4.0x | 8.0x | 16.0x |
| Diluted shares | 49M | 49M | 49M |
| Net debt | $1.10B | $1.10B | $1.10B |
| Implied P/E † | — | — | — |
| 2030 Price | $39.87 | $102.35 | $227.33 |
| NPV @ 10% | $25.69 | $65.96 | $146.50 |
† Implied P/E: Multiples remain elevated across all three scenarios because GRAL is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $102.35 base case
GRAL catalysts and risks
Growth catalysts
+ FDA Premarket Approval (PMA) decision for Galleri test (submitted January 2026; decision expected 2026-2027)
+ NHS-Galleri and PATHFINDER 2 data presentations at 2026 ASCO Annual Meeting showing clinical utility and cancer detection rates
+ Epic EHR integration (announced April 2026) enabling broader physician adoption across U.S. health systems
+ Payer reimbursement agreements and NHS implementation discussions potentially unlocking 10x+ volume expansion
+ Commercial partnerships (Hims & Hers, Superpower) scaling self-pay and preventive health channels
Key risks
- NHS-Galleri trial showed mixed results (failed primary endpoint on mortality reduction; did show 4x higher cancer detection rate). Regulatory pathway clarity uncertain until FDA decision.
- Massive ongoing cash burn (-$95.2M net loss Q1 2026 alone) despite revenue growth. Path to profitability not disclosed; 2030 cash runway guideline implies continued losses through 2029.
- Reimbursement uncertainty: multi-cancer screening tests face pricing pressure and payer adoption challenges. Without insurance coverage, addressable market limited to high-income self-pay segment (~$1-2B annually in U.S.).
- Competitive threat: Exact Sciences (EXAS) Galleri competitor; large diagnostics players (Quest, LabCorp) entering MCED space with distribution advantages.
- Clinical validation risk: further negative trial data or safety signals could derail FDA approval or payer adoption.
Methodology · GRAIL, LLC 2030 stock forecast model
GRAIL, LLC 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 8 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (13% cumulative for GRAL by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($1.10B by 2030) |
| 3. Time value | NPV calculated using 10% WACC (sector fallback) |
| 4. Multiple framework | P/S compresses with scale: bear 4.0x / base 8.0x / bull 16.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
GRAL price target FAQ
What is the GRAL price target for 2030?
WallStSmart's GRAIL, LLC 2030 base case is $102.35 per share, with a bull case of $227.33 and bear case of $39.87. The NPV of the base case discounted to today at 10% WACC is $65.96.
How is the GRAIL, LLC 2030 stock forecast calculated?
The GRAL 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the GRAL price target account for dilution?
GRAIL, LLC is projected to grow diluted share count from 43M to 49M by 2030 (a 13% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 13%.
What is the analyst consensus on GRAL stock?
8 analysts cover GRAL with an average 12-month price target of $67.88. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.